PET/CT helps predict therapy effectiveness in pediatric brain tumors

May 2, 2017, Society of Nuclear Medicine
Top row: Zr-89-bevacizumab PET (144 hrs p.i.) fused with T1-Gd weighted MRI per patient; middle row: T1-Gd weighted MRI; lower row: T2-weighted/FLAIR MR-images. Five tumors show variable uptake of Zr-89-bevacizumab (white arrows), with both PET negative and positive areas within each tumor. Two primary tumors are completely PET negative (Fig. 1C and 1E), while the T2 weighted images show tumor infiltration in the whole pons of both patients. In the middle row, the red arrows represent the areas of contrast enhancement within the tumor. In four out of five primary tumors, the PET-positive area corresponds with the contrast-enhancing area on MRI of the tumors (Fig. 1A, 1B, 1F and 1G). In Fig. 1C, the tumor shows an MRI contrast-enhancing area, while there is no Zr-89-bevacizumab uptake. Fig. 1D shows a PET positive tumor, while no Gd-enhancement is observed on MRI. Credit: Sophie Veldhuijzen van Zanten and Marc Jansen, VU University Medical Center, Amsterdam, The Netherlands

Brain cancers are difficult to treat, and it can be hard to predict whether a therapy will be effective. When the patient is a child, it's even more important to predict the potential effectiveness of a drug before beginning treatment. In this first ever molecular drug-imaging study in children, researchers in The Netherlands used whole-body positron emission tomography/computed tomography (PET/CT) scans to determine whether bevacizumab (Avastin) treatment of diffuse intrinsic pontine glioma (DIPG) in children is likely to be effective. The study is featured in the May 2017 issue of The Journal of Nuclear Medicine.

"Children with DIPG have a very poor prognosis, with less than 10 percent of the surviving two years from diagnosis," explains Guus A. van Dongen, PhD, of VU University, Medical Center, Amsterdam, The Netherlands. "These tumors are resistant to all kinds of therapies. Chemotherapy, as well as new targeted therapies, may not reach the tumor due to the location within the brainstem."

For the study, researchers investigated whether bevacizumab can reach the tumor in children with DIPG by measuring the tumor uptake of zirconium-89 (Zr-89)-labeled bevacizumab with PET. In addition, they evaluated the safety of the procedure and determined the optimal timing of imaging.

Two weeks after completing radiotherapy, seven patients (age range: 6-17) were given whole-body PET/CT scans performed at 1, 72 and 144 hours post-injection. The optimal moment of scanning was found to be 144 hours post-injection. The patients also underwent contrast (gadolinium)-enhanced MRI.

"The results showed that indeed there is considerable heterogeneity in uptake of Zr-89-labeled bevacizumab among patients and within tumors," Van Dongen points out. "This non-invasive in vivo quantification of drug distribution and tumor uptake may help to predict therapeutic potential, as well as toxicity, and could help develop strategies for improving drug delivery to tumors."

Van Dongen adds, "Children with and other solid cancers are particularly likely to benefit from molecular drug imaging, as drugs without therapeutic effect—based on a lack of drug-uptake in the —may cause life-long side effects. Molecular drug imaging will open avenues for administering the right to the right patient at the most appropriate stage of the disease."

Explore further: Team examines use of antiparasitic drug as new treatment for brain tumors

More information: Marc H. Jansen et al, Molecular Drug Imaging:Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma, Journal of Nuclear Medicine (2017). DOI: 10.2967/jnumed.116.180216

Related Stories

Team examines use of antiparasitic drug as new treatment for brain tumors

April 11, 2017
Marc Symons, PhD, professor in The Feinstein Institute for Medical Research's Karches Center for Oncology Research, is examining if a common medication administered to treat pinworms, could replace the current treatment used ...

Molecule stops fatal pediatric brain tumor

February 27, 2017
Northwestern Medicine scientists have found a molecule that stops the growth of an aggressive pediatric brain tumor. The tumor is always fatal and primarily strikes children under 10 years old.

Treatment with Alk5 inhibitor improves tumor uptake of imaging agents

May 5, 2016
Imaging probes that specifically target tumors can provide more sensitive and relevant information about the tumor compared to conventional, non-specific probes. Additionally, targeted probes can improve tumor detection, ...

PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors

July 5, 2011
A non-invasive PET imaging technique may identify lung cancers that respond best to tyrosine kinase inhibitors (TKIs), allowing doctors to better select patients for personalized therapy, according to research presented at ...

Photoacoustic and magnetic resonance imaging visualizes blood flow and oxygenation status in brain tumor tissue

July 20, 2016
Cancer diagnostics and therapy monitoring have moved into a new dimension through A*STAR research, which has developed a high-resolution and noninvasive approach to visualize brain tumors by combining photoacoustic with magnetic ...

Recommended for you

More than 2,500 cancer cases a week could be avoided

March 23, 2018
More than 135,500 cases of cancer a year in the UK could be prevented through lifestyle changes, according to new figures from a Cancer Research UK landmark study published today.

Metastatic lymph nodes can be the source of distant metastases in mouse models of cancer

March 22, 2018
A study by Massachusetts General Hospital (MGH) investigators finds that, in mouse models, cancer cells from metastatic lymph nodes can escape into the circulation by invading nodal blood vessels, leading to the development ...

Could a pap test spot more than just cervical cancer?

March 22, 2018
Pap tests have helped drive down rates of cervical cancer, and a new study suggests they also could be used to detect other gynecologic cancers early.

Researchers identify compound to prevent breast cancer cells from activating in brain

March 22, 2018
Researchers at Houston Methodist used computer modeling to find an existing investigational drug compound for leukemia patients to treat triple negative breast cancer once it spreads to the brain.

Researchers examine role of fluid flow in ovarian cancer progression

March 22, 2018
New research from Virginia Tech is moving physicians closer to pinpointing a predictor of ovarian cancer, which could lead to earlier diagnosis of what is know as the "silent killer."

Probing RNA epigenetics and chromatin structures to predict drug resistance in leukemia

March 22, 2018
Drug resistance is a major obstacle to effective treatment for patients with cancer and leukemia. Epigenetic modifying drugs have been proven effective for some patients with hematologic malignancies, such as myelodysplastic ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.